Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
2.
Joint Bone Spine ; 90(2): 105527, 2023 Jan 25.
Article in English | MEDLINE | ID: mdl-36706478
3.
Cartilage ; 14(2): 125-135, 2023 06.
Article in English | MEDLINE | ID: mdl-36443990

ABSTRACT

RATIONALE: Viscosupplementation (VS) with hyaluronic acid is widely used in the management of knee osteoarthritis. There is no clear recommendation on the decision-making to achieve VS. DESIGN: Based on extensive research of the literature and expert opinion, the members of the EUROVISCO (European Viscosupplementation Consensus Group) task force were asked to give their degree of agreement with 60 issues, using a Delphi method. RESULTS: The expert panel achieved unanimous agreement in favor of the following statements: It is recommended to assess pain on a visual or 10-point numeric scale before considering VS. VS can be considered for patients with pain scores between 3 and 8. A standard x-ray must be obtained before the decision of VS. If the x-ray is normal, osteoarthritis must be confirmed by MRI or computed tomography (CT) arthrogram before considering VS. The aims of VS are relieving pain, improving function, and reducing non-steroidal anti-inflammatory drug (NSAID) consumption. The use of VS must not be considered for treating an osteoarthritis flare. VS can be envisaged as a first-line pharmacological treatment in patients having a contra-indication to NSAIDs or analgesics. VS can be considered in patients with contra-indications to arthroplasty. In the case of severe comorbidities (diabetes, hypertension, gastrointestinal disorders, renal failure), VS can avoid the use of potentially dangerous treatments. VS can be considered in patients receiving antiplatelet agents, vitamin K antagonists, and direct factor Xa or thrombin inhibitors. Five other statements obtained a high level of consensus. CONCLUSION: These recommendations, illustrated in a decision algorithm, have been established to help practitioners in the decision-making of knee VS.


Subject(s)
Osteoarthritis, Knee , Viscosupplementation , Humans , Viscosupplementation/methods , Osteoarthritis, Knee/diagnostic imaging , Osteoarthritis, Knee/drug therapy , Hyaluronic Acid/therapeutic use , Injections, Intra-Articular , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Pain/drug therapy
4.
Joint Bone Spine ; 90(2): 105515, 2023 03.
Article in English | MEDLINE | ID: mdl-36529421

ABSTRACT

Musculoskeletal corticosteroid injections are widely performed, although the exact practice varies greatly due to advances in knowledge and techniques. This justifies updating and drawing up good practice recommendations. Using a consensus model formalized by the French National Authority for Health (HAS) and based on a literature review that resulted in a "white book", 13 recommendations were developed by a group of experts. These recommendations were then sent online to 48 specialists for evaluation, 27 of whom were rheumatologists and 15 of whom were general practitioners. These recommendations were also presented at the 34th annual meeting of the French Society for Rheumatology (SFR) (Paris, December 2021) at a symposium attended by a hundred or so rheumatologists, who voted on these recommendations in person. The results are presented as an overall score out of 10, a median out of 10 and as tertiles. The agreement was excellent for 10 of these 13 recommendations, with mean values of 8.5 to 9.1 out of 10, median values of 9 or 10 out of 10 and agreement of 91.7% to 97.9%, which corresponds to a consensus. The 3 other recommendations were broadly supported but were the subject of more debate. One relates to patient information (mean 7.3/10, median 8/10, upper tertile 72.9%) with discussion about the waiting period. Another related to the summary report (mean 8.4/10, median 9, upper tertile 91.7%) with discussions about its content and the need to specify the lot number of the injected product. The last one related to periprosthetic injections and the need to consult and get approval from a specialist (mean 8.0/10, median 8, upper tertile 83.3%) with mostly the general practitioners having reservations. In all, there is a very strong consensus among the musculoskeletal corticosteroid injection experts and specialists consulted, which justifies them being taken into consideration to improve our daily practice.


Subject(s)
Rheumatology , Humans , Rheumatologists , Adrenal Cortex Hormones
5.
Cartilage ; 13(1_suppl): 1696S-1701S, 2021 12.
Article in English | MEDLINE | ID: mdl-34696623

ABSTRACT

OBJECTIVES: This work studied if and how current clinical practice agrees with European Viscosupplementation Consensus Group (EUROVISCO) recommendations and how this agreement might be different according to physician's specialization. In addition, this work aimed to identify key decision factors that practitioners consider in their decision to retreat or not a patient with hyaluronic acid viscosupplementation. METHODS: Practitioners have been invited by e-mail to participate in an online exercise on viscosupplementation retreatment. They received a fictional patient case at random among a set of predefined fictional cases. The platform asked the practitioner if he/she would retreat the patient with viscosupplementation or not. To take a decision, the practitioner could select questions among a list of predefined questions. Among them, some were related to criteria used in the EUROVISCO decision tree and others served as confounding factors. RESULTS: A total of 506 practitioners participated to the exercise, of which 399 gave their decision about the case assigned to them by the platform. The observed agreement between practitioner decisions and EUROVISCO recommendations was 58.89 ± 4.95% (95% confidence interval [CI]). Overall, the decision to retreat was taken in 47.87% of the cases, while the EUROVISCO guidelines follow-up would have led to 55.89% retreatment for the same cases (P = 0.03). CONCLUSIONS: In current practice, physicians tended to reinject their patients less than recommended, although EUROVISCO guidelines for viscosupplementation retreatment consider decision criteria that clearly correspond to those of practitioners in real life. These include the patients' willingness to be treated or the patients' perception of the effectiveness of the treatment.


Subject(s)
Osteoarthritis, Knee , Viscosupplementation , Consensus , Female , Humans , Hyaluronic Acid/therapeutic use , Osteoarthritis, Knee/drug therapy , Retreatment , Viscosupplements/therapeutic use
6.
Ther Adv Musculoskelet Dis ; 13: 1759720X211018605, 2021.
Article in English | MEDLINE | ID: mdl-34104232

ABSTRACT

Viscosupplementation (VS) is a symptomatic treatment for knee and other joint osteoarthritis (OA). Despite a long history of use, conflicting opinions remain on the best clinical indications and the most appropriate patients to be treated with intra-articular hyaluronic acid (IA-HA), the optimal dosing regimen and the modalities of retreatment. A multidisciplinary committee of European experts on OA (EUROVISCO) was constituted to formulate recommendations, aimed at helping physicians in the decision-making and the optimal achievement of VS. Before each session members were tasked to collate an exhaustive literature review. Level of evidence and strength of recommendation were based on the level of agreement for each item according to the Delphi method. In 2015, a consensus position was proposed for 24 statements. Among those that obtained a consensual agreement, the working group stressed that VS is effective in mild/moderate knee OA but is not an alternative to surgery in advanced OA, and that dosing regimen must be supported by controlled trials. In 2018, two decision algorithms for the retreatment with IA-HA in knee OA were published. Among the key recommendations, the experts recommended to re-treat every year patients with high risk of OA progression, even if not symptomatic. In 2020, EUROVISCO published two sets of recommendations for the design of clinical trials on the disease-modifying effect of VS and for optimizing the results of VS. The working group underlined that an accurate analysis of radiological features and symptoms and a careful clinical examination may improve the chances of success of VS, as well as good technique of injection and the use of imaging guidance. Based on the exhaustive analysis of the literature and their own clinical experience, the EUROVISCO experts offer a wide range of recommendations intended to help practitioners, particularly in certain cases where the specific characteristics of the patients make the therapeutic decision difficult.

7.
Knee Surg Sports Traumatol Arthrosc ; 29(10): 3195-3210, 2021 Oct.
Article in English | MEDLINE | ID: mdl-32583023

ABSTRACT

PURPOSE: There has been much debate regarding the use of intra-articular injections of platelet-rich plasma (PRP) as symptomatic treatment for knee osteoarthritis. The objective of this consensus was to develop guidelines for PRP injections in knee osteoarthritis according to the French National Authority for Health recommendations. METHODS: Fifteen physicians from different French-speaking countries (10 rheumatologists, 4 specialists in rehabilitation and sports medicine and 1 radiologist) were selected for their expertise in the areas of PRP and osteoarthritis. A comprehensive literature review was conducted on Medline including all published therapeutic trials, open studies, meta-analysis and systematic reviews focusing on the effects of PRP in knee OA, as well as fundamental studies concerning the characteristics of the various types of PRP and their mechanisms, indexed before April 2019. Using the method recommended by the French National Authority for Health inspired by the Delphi consensus process, 25 recommendations were finally retained and evaluated. The recommendations were classified as appropriate or not appropriate, with strong or relative agreement, or uncertain if a consensus was not achieved. RESULTS: Among the 25 recommendations selected, the main ones are the following: (1) Intra-articular injections of PRP are an effective symptomatic treatment for early to moderate knee osteoarthritis. This recommendation was considered appropriate with a relative agreement (Median = 8; rank = 6-9). Level of evidence 1A. (2) A PRP treatment sequence in knee osteoarthritis may include 1-3 injections. This recommendation was considered appropriate with a strong agreement (Median = 9; rank = 7-9). Level of evidence 1A. (3) Leucocytes-poor PRP should be preferred in knee osteoarthritis. This recommendation was considered appropriate with a relative agreement (Median = 8; rank = 5-9). Level of evidence 5. (4) Intra-articular PRP knee injections should be performed under ultrasound or fluoroscopic guidance. This recommendation was considered uncertain with no consensus (Median = 8; rank = 3-9). Level of evidence 5. (5) PRP should not be mixed with an anesthetic or intra-articular corticosteroid. This recommendation was considered appropriate with a relative agreement (Median = 9; rank = 6-9). Level of evidence 5 CONCLUSION: Those 25 recommendations should standardize and facilitate the use of IA PRP injections, which are considered by experts as an effective treatment especially in early or moderate knee OA. Although a strong or relative agreement from the experts was obtained for most of the recommendations, many of them had a very low level of evidence (Level 5) and were principally based on the clinical experience of the experts.


Subject(s)
Osteoarthritis, Knee , Platelet-Rich Plasma , Consensus , Humans , Hyaluronic Acid , Injections, Intra-Articular , Knee Joint , Osteoarthritis, Knee/drug therapy , Treatment Outcome
9.
Cartilage ; 11(1): 47-59, 2020 01.
Article in English | MEDLINE | ID: mdl-29926748

ABSTRACT

OBJECTIVES: The 3 aims of the work were to identify population subgroups that can benefit the most from viscosupplementation (VS), to provide recommendations on injection techniques, and to discuss VS appropriateness in clinical situations that are commonplace in daily practice. METHODS: The task force members voted on their degree of agreement on 27 statements, 36 recommendations, and 22 clinical scenarios using a 9-point scale. The strength of agreement/appropriateness/recommendation (SOA/SOR) was classified as strong if the median agreement score was ≥8. The level of consensus (LOC) was also obtained. RESULTS: Among the assumed predictors for VS failure, obesity, radiographic severity, large synovial fluid effusion, severe patellofemoral involvement, major malalignment, and gross joint instability received a large majority of agreements. The lateral mid-patellar approach was recommended for knee injection. Imaging guidance was unanimously recommended for hip and ankle. Agreement was achieved to strictly respect the dosing regimen proven by controlled trials. There was agreement for treating with VS patients with mild to moderate knee and hip OA, with normal weight or moderate overweight, insufficiently improved by first-line therapies, or who do not wish get oral treatment or who have contraindications to pain killers. The group considered the patient's wishes as a key element in therapeutic decision making. CONCLUSION: Based on literature data and clinical experience, the EUROVISCO group proposed a set of recommendations for optimizing the results of VS, aimed to help practitioners, especially in some cases in which the patients' specificities make the therapeutic decision difficult.


Subject(s)
Hyaluronic Acid/administration & dosage , Osteoarthritis/drug therapy , Practice Guidelines as Topic , Viscosupplementation/standards , Viscosupplements/administration & dosage , Advisory Committees , Clinical Decision-Making , Consensus , Europe , Humans , Treatment Outcome , Viscosupplementation/methods
10.
Cartilage ; 11(1): 60-70, 2020 01.
Article in English | MEDLINE | ID: mdl-29972025

ABSTRACT

OBJECTIVES: Hyaluronic acid viscosupplementation is a commonly used intra-articular treatment for osteoarthritis (OA). Some recent preclinical and clinical trials have demonstrated a potential for its disease-modifying effects. The goal of this expert opinion, consensus-driven exercise is to provide guidelines for the design and conduct of clinical trials assessing the disease-modifying effect of viscosupplementation in the knee. METHODS: The EUROVISCO group constitutes 10 members who had expertise in clinical research methodology in the field of OA and viscosupplementation. They initially drafted issues through an iterative process and had to vote on their degree of agreement on these recommendations. The scores were pooled to generate a median agreement score for each recommendation. RESULTS: The document includes 31 recommendations regarding study population, imaging, clinical and biological assessment of disease-modifying effects of viscosupplementation. Agreements were reached on some recommendations. In particular, the experts reached unanimous agreement on double-blind study design, imaging primary outcomes, time interval between 2 radiographs, x-ray procedure standardization, and the combined use of imaging and biological markers. The group did not recommend the use of ultrasonography, computed tomography (CT) scan and CT arthrography as a tool for OA diagnosis or to assess progression over time. CONCLUSION: In summary, the working group identified 31 recommendations that represent the current best practices regarding clinical trials that target the assessment of viscosupplementation disease-modifying effects in patients with knee OA. These recommendations integrate new imaging technologies and soluble biomarkers.


Subject(s)
Drug Monitoring/methods , Hyaluronic Acid/administration & dosage , Osteoarthritis, Knee/drug therapy , Viscosupplementation/methods , Viscosupplements/administration & dosage , Advisory Committees , Aged , Aged, 80 and over , Biomarkers/analysis , Female , Humans , Knee Joint/drug effects , Male , Middle Aged , Practice Guidelines as Topic , Randomized Controlled Trials as Topic , Treatment Outcome
12.
Semin Arthritis Rheum ; 48(4): 563-572, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30072113

ABSTRACT

OBJECTIVES: There is a discrepancy between evidence in support of the widespread use of intra-articular hyaluronic acid (IAHA) to treat knee osteoarthritis (OA) in clinical practice, and the often discordant recommendations from multiple international guideline committees, which requires further investigation. METHODS: We conducted a literature review to determine the strength of evidence in support of the efficacy and safety of IAHA, from randomized controlled trials and meta-analyses. RESULTS: Our analysis shows that IAHA provides a moderate symptomatic benefit to knee OA patients and without major safety concerns. In fact, IAHA may offer one of the best benefit/risk ratios among pharmacologic options, as measured by improvements in knee OA health outcomes, overall gain in quality-adjusted life years and substantial delays in time to total knee replacement. CONCLUSIONS: We advocate for the consideration of recommending IAHA injection as a treatment option in the management of knee OA, tailored by disease stage and patient phenotype. Future research efforts should focus on identification of OA patient subgroups that demonstrate a more robust response to IAHA, determination of long-term effects of repeat IAHA injections on patient-reported outcomes and total knee replacement-sparing effect, further elucidation of disease-modifying effects, and the potential for combination therapy with other pharmacologic and non-pharmacologic therapies to optimize the management of knee OA.


Subject(s)
Hyaluronic Acid/therapeutic use , Knee Joint/drug effects , Osteoarthritis, Knee/drug therapy , Viscosupplementation , Viscosupplements/therapeutic use , Humans , Hyaluronic Acid/administration & dosage , Injections, Intra-Articular , Treatment Outcome , Viscosupplements/administration & dosage
13.
Cartilage ; 9(3): 263-275, 2018 07.
Article in English | MEDLINE | ID: mdl-29110511

ABSTRACT

Background Viscosupplementation (VS) is a symptomatic treatment of knee osteoarthritis. Although systematic reviews of its repeat use showed favorable benefit/risk ratio, no study has focused on the indication of retreatment. Methods A task force was created to look at issues regarding retreatment with VS in knee osteoarthritis. An attempt was made to reach consensus on several issues: (1) to define treatment "success" and "failure," (2) to determine when to retreat patients successfully treated by a previous VS, (3) to determine how to retreat patients in whom VS failed, (4) to define what to do in case of adverse reaction following previous VS, and (5) to examine the interests of soluble biomarkers to manage retreatment. After debate and review of literature the working group voted on 88 issues. Two "decision trees" were built based on the results of the votes. Results In case of failure, the authors draw attention to the need of a rigorous clinical and radiological analysis, and consider evidence-based medicine. When VS was previously successful, retreatment can be considered after recurrence or increase in pain. However, in subjects with high risk of disease progression, in young patients, and in professional sportsmen, retreatment could be considered systematically, because of the probability of hyaluronic acid to slow osteoarthritis progression. Evidence on soluble biomarkers was not considered as enough strong to support their use as decision tools for patient retreatment. Conclusion The decision algorithms are intended to facilitate consideration of the therapeutic options, in patients with knee osteoarthritis previously treated with VS.


Subject(s)
Hyaluronic Acid/therapeutic use , Osteoarthritis, Knee/therapy , Retreatment/ethics , Viscosupplementation/methods , Algorithms , Biomarkers/metabolism , Consensus , Decision Making , Disease Progression , Evidence-Based Medicine , Humans , Hyaluronic Acid/administration & dosage , Injections, Intra-Articular/methods , Treatment Outcome , Viscosupplementation/adverse effects , Viscosupplements/administration & dosage , Viscosupplements/therapeutic use
15.
Semin Arthritis Rheum ; 45(2): 140-9, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26094903

ABSTRACT

Viscosupplementation (VS) with hyaluronic acid is currently used by physicians to treat osteoarthritis. However, many aspects of this treatment remain questionable and subject of controversy. A group of 8 experts in this field, from European countries, met to debate on 24 statements previously listed by the group members. Based on an extensive research of the literature and expert opinion, a consensus position has been proposed for each statement. Agreement was achieved on some recommendations. In particular, the expert achieved unanimous agreement in favor of the following statements: VS is an effective treatment for mild to moderate knee OA; VS is not an alternative to surgery in advanced hip OA; VS is a well-tolerated treatment of knee and other joints OA; VS should not be used only in patients who have failed to respond adequately to analgesics and NSAIDs; VS is a "positive" indication but not a "lack of anything better" indication; the dosing regimen must be supported by evidence-based medicine; cross-linking is a proven means for prolonging IA residence time of HA; the best approach to inject accurately knee joint is the lateral mid-patellar one; when VS is performed under fluoroscopy, the amount of radiopaque contrast agent must be as low as possible to avoid viscosupplement dilution. These clear recommendations have been established to help practitioners in the use of viscosupplementation.


Subject(s)
Hyaluronic Acid/therapeutic use , Osteoarthritis/drug therapy , Viscosupplementation/methods , Viscosupplements/therapeutic use , Consensus , Disease Management , Evidence-Based Medicine , Humans , Treatment Outcome
16.
J Belg Soc Radiol ; 99(2): 3-12, 2015 Dec 30.
Article in English | MEDLINE | ID: mdl-30128425

ABSTRACT

Thanks to its excellent spatial resolution and dynamic aspect, ultrasound of the shoulder allows an optimal evaluation of tendon, muscle and nerve' structures in shoulder pain. Through this article and owing to inter-observer reproducibility, we will describe an ultrasound standardized protocol (posterior, anterior, global plane) in basic first ultrasounds (ie without tendon abnormality of the supra/infra spinatus, the biceps and subscapularis).

17.
Rev Prat ; 62(5): 643-50, 2012 May.
Article in French | MEDLINE | ID: mdl-22730791

ABSTRACT

Intra-articular injections are part of long-standing symptomatic treatment of osteoarthritis. Numerous products were injected into arthritic joints to whether analgesic, anti-inflammatory or disease-modifying antirheumatic drug. Corticosteroids and viscosupplements are the only permitted as they are validated by controlled studies and part of the treatment of osteoarthritis recommended by scientific societies. The intra-articular injections are effective in limb osteoarthritis, short term for corticosteroids, in the longer term but more delayed, smaller and less constant for viscosupplements, provided they are properly performed. These local treatments do not have to summarize the treatment of osteoarthritis, but integrated into a comprehensive care without neglecting the non-pharmacologic measures. Their benefit should be reassessed regularly for each patient and their effectiveness is often decreased with the progression of osteoarthritis when it does not stabilize. The injection conditions must be rigorous to ensure greater efficiency and reduce the side effects which are rare and usually benign.


Subject(s)
Analgesics/administration & dosage , Anti-Inflammatory Agents/administration & dosage , Antirheumatic Agents/administration & dosage , Osteoarthritis/drug therapy , Viscosupplements/administration & dosage , Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/adverse effects , Analgesics/adverse effects , Anti-Inflammatory Agents/adverse effects , Humans , Hyaluronic Acid/administration & dosage , Hyaluronic Acid/adverse effects , Injections, Intra-Articular/adverse effects , Osteoarthritis/diagnosis , Practice Patterns, Physicians' , Risk Assessment , Time Factors , Viscosupplements/adverse effects
18.
Rev Prat ; 59(4): 463-8, 2009 Apr 20.
Article in French | MEDLINE | ID: mdl-19462863

ABSTRACT

Tendinopathy of the gluteus medius tendon is the main cause of great trochanter pain syndrom. Recent clinical, ultrasonographic and MRI study, allow to distinguish anterior lesions which concern the lateral part of the gluteus medius tendon, almost always associated with tendinopathy of the gluteus minimus tendon, from tendinopathy of the main tendon of the gluteus medius. Tears of the main tendon of the gluteus medius are the serious disabling consequence of that pathology and must be avoid by early medical and functional treatment with very moderate use of intrabursal corticosteroid injections. In few cases without improvement after medical treatment, surgery is indicated and includes bursectomy of the trochanteric bursa and tendinoplasty.


Subject(s)
Tendinopathy , Buttocks , Diagnosis, Differential , Humans , Tendinopathy/diagnosis , Tendinopathy/etiology , Tendinopathy/therapy
19.
Joint Bone Spine ; 74(5): 453-60, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17921022

ABSTRACT

INTRODUCTION: Medicoeconomic data on treatments for osteoarthritis are scant. We investigated the impact of hyaluronic acid therapy on the cost of management of knee osteoarthritis. Our primary objective was to compare medical costs (admissions, outpatient visits, investigations, and treatments) and non-medical costs (sick leaves and transportation) from the perspective of the national health insurance system during the 3 months before and the 6 months after three intraarticular injections of hyaluronic acid. Our secondary objective was to evaluate treatment benefits in terms of pain, function, and quality of life. METHODS: Observational, multicenter, longitudinal, before-after study of the medical and economic effects of hyaluronic acid therapy for symptomatic knee osteoarthritis. RESULTS: Of the 296 assessable patients (mean age, 69 years; 30% with obesity; 65% women), only 5% of patients were withdrawn prematurely from the study. Significant improvements in the Lequesne index were found 3 and 6 months after treatment; the improvement was greater than 50% in over half the patients. Pain and quality-of-life scores improved significantly. Total cost of the disease decreased from 334 euros for the 3 pretreatment months to 295 euros and 233 euros for posttreatment months 1-3 and 4-6, respectively. CONCLUSION: The costs of knee osteoarthritis decreased during the 6 months after Suplasyn therapy, indicating that the cost of the medication was more than offset by the decreased need for other treatments. Concomitantly, clinical benefits were obtained. Under the conditions of everyday practice, hyaluronic acid may provide medical benefits at an acceptable cost.


Subject(s)
Hyaluronic Acid/economics , Hyaluronic Acid/therapeutic use , Osteoarthritis, Knee/drug therapy , Osteoarthritis/drug therapy , Osteoarthritis/economics , Aged , Cost of Illness , Female , France/epidemiology , Humans , Longitudinal Studies , Male , Osteoarthritis/epidemiology , Osteoarthritis, Knee/economics , Osteoarthritis, Knee/epidemiology , Pain , Pain Measurement , Quality of Life , State Medicine
20.
Rev Prat ; 52(6): 627-31, 2002 Mar 15.
Article in French | MEDLINE | ID: mdl-12001413

ABSTRACT

The hip region is the seat of a rich and common periarticular pathology, with a variable involvement, depending of the location, and needs better knowledge. Anyway the clinical examination takes the major place in the diagnostic. Trochanteric bursitis and tendinitis are the more common clinical syndrome in that regional pathology. Local injections of corticosteroid are still the mean modality of the conservative treatment but are not sufficient to avoid recurrence or chronicity which may lead to tendon tears. A better knowledge of the physiopathology will lead to a better and early recovery. Apatite calcifications are not rare around the hip. Great trochanter is the first location, but the femoral insertion of the gluteus maximus and vastus lateralis on the linea aspera, the lateral side of the acetabulum and the ischial tuberosity are worth known. Iliopsoas bursitis, which has some analogy with the popliteal cyst, is often underrecognized, like ischial bursitis and tendinopathy.


Subject(s)
Bursitis/pathology , Hip Joint/pathology , Tendinopathy/pathology , Bursitis/diagnosis , Bursitis/therapy , Calcinosis , Diagnosis, Differential , Humans , Recurrence , Tendinopathy/diagnosis , Tendinopathy/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...